Elanco Animal Health Inc (ELAN) · Nov 6, 2026 · Earnings

Elanco earnings beat and raise as pet-health launches accelerate

Beat — Adjusted EPS $0.27 vs ~$0.20 consensus; revenue $1.265B vs ~$1.21B

Elanco earnings beat consensus, with Zenrelia and Credelio Quattro driving growth, margins and another full-year guidance raise.

Elanco is in a product-led growth transition: it is trying to replace older portfolio pressure with newer pet-health launches, while integrating AHV International and reducing leverage. The prior quarter had already established a beat-and-raise pattern, with innovation products and faster deleveraging becoming the central operating story.

This was a broad operational beat, not just a low-quality EPS surprise. Revenue reached $1.265 billion, ahead of the published consensus of roughly $1.21 billion, while adjusted EPS was $0.27 versus approximately $0.20 expected. Adjusted EBITDA also grew 23% year over year to $243 million, supported by stronger pricing and mix.

Q3 2026Q3 2025Consensus
Revenue (Financial Highlights)$1,265M (+11%)$1,137M~$1,210M
Adjusted EBITDA (Financial Highlights)$243M (+23%)$198M
Adjusted EPS (Financial Highlights)$0.27 (+42%)$0.19~$0.20

The underlying mix was especially constructive. Pet Health grew 14% organically, with Zenrelia and Credelio Quattro continuing to gain clinic adoption and share; Farm Animal was slower but still grew organically. Poultry remained the notable weak spot, down 7%, but it was outweighed by the faster-growing pet and ruminant businesses.

Management converted the quarter’s outperformance into a meaningful guidance raise. The new full-year midpoint is about $5.168 billion of revenue, $1.058 billion of adjusted EBITDA and $1.185 of adjusted EPS, up from roughly $5.115 billion, $1.023 billion and $1.13 previously. This is more than a routine reaffirmation: the company also lifted expected 2026 organic constant-currency growth to approximately 8% from 6%-7% and raised its expected margin improvement.

November 2026 guidanceAugust 2026 guidance
Revenue (Full-Year Guidance)$5,155M-$5,180M$5,090M-$5,140M
Adjusted EBITDA (Full-Year Guidance)$1,050M-$1,065M$1,010M-$1,035M
Adjusted EPS (Full-Year Guidance)$1.17-$1.20$1.10-$1.16

The balance-sheet improvement adds credibility to the operating progress. Net leverage reached 2.9x at quarter-end, earlier than expected, giving Elanco more flexibility to allocate capital while continuing to fund launches and R&D. That matters because the growth plan still depends on sustained investment rather than simple cost cutting.

Bottom line: Elanco delivered a genuine beat across sales and adjusted profit, with its newer pet-health products driving the upside and management raising the full-year bar again. The story is strengthening from portfolio transition to demonstrated execution, although poultry weakness and continued launch spending remain secondary offsets.

What to watch next

Q4 results and 2027 outlook, early 2027

Original filing on SEC EDGAR

More Elanco Animal Health Inc news

Elanco earnings beat and raise as pet-health launches accelerate | ELAN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.